Palamu health centres stop distribution of 38L calcium and vitamin D3 tablets
Daltonganj: People going to the govt-run health centres in Palamu district would no longer be given calcium (500mg) and vitamin D3 (205 IU) tablets that were procured in the 2024-25 financial year as these were found "not of standard quality", officials at the district health department said on Tuesday.
A Jamshedpur-based pharmaceutical company had supplied over 38 lakh tablets of calcium (500mg) and vitamin D3 (205 IU) to the Palamu district health department for the Medinirai Medical College and Hospital (MMCH), sub-divisional hospitals, community health centres, and sub-health centres located in the district under the
National Health Mission
(NHM). The firm had produced a 'certificate of analysis' issued by the Oxigen Analytical Laboratories, Himachal Pradesh, a govt-approved test house, declaring these two medicines as of "standard quality".However, Palamu civil surgeon Dr Anil Kumar said, "The drug inspector tested samples of these two medicines in Central Drugs Laboratory, Kolkata, and the results 'did not meet the standard quality'.
Instructions were issued to all govt health centres in the district to immediately stop the distribution of these two medicines among the patients.
"The Jamshedpur-based firm, in its letter to the health department, agreed to replace calcium, and vitamin D3 tablets totalling 2,96,400, 2,96,400, and the 2,92,200 of the GTL 1258, 1288, and 1296 batches, respectively, he added.Asked about another 14 batches of these two medicines that did not meet the standard quality, the civil surgeon said, "The pharmaceuticals distribution company is legally bound to replace the tablets of all the 17 batches identified in the test."Dr Kumar said, "The solubility of these two medicines doesn't conform to the set standards. The entire exercise for analysis, quality assurance, and test report of these two medicines was completed in a little over 100 days, beginning January."Asked if any action would be taken against the distribution company, Dr Kumar said, "The matter has been reported to the NHM director and the director of medicine of the state medicine control directorate, Ranchi."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
35 minutes ago
- Business Standard
Wockhardt eyes $9 bn market opportunity for novel antibiotic Zaynich
Mumbai-based pharmaceutical major Wockhardt, which is set to launch a new class of antibiotic, Zaynich, in India this year, estimates a total addressable market opportunity of $9 billion. This includes a $7-billion market in the US and Europe, and a ₹17,000-crore opportunity in India. The company's stock rose 2.4 per cent on the BSE on Thursday following an investor presentation outlining its growth plans for the next three to five years. Zaynich (or WCK 5222) is a key research candidate in Wockhardt's pipeline. It has completed global Phase 3 clinical trials, demonstrating a 20 per cent higher (statistically superior) composite cure rate compared to Meropenem, the current gold standard in antibiotics. Wockhardt claims Zaynich is the first new class of antibiotic in over 30 years to treat gram-negative infections. The drug has already saved 51 lives under compassionate use, including three in the US, where patients had failed all existing therapies. Zaynich is indicated for complicated urinary tract infections (UTIs), hospital-acquired and ventilator-associated bacterial pneumonia, bloodstream infections, and complicated intra-abdominal infections. The company expects approval from the Drugs Controller General of India (DCGI) shortly and plans to launch the drug in the second half of this financial year. Wockhardt has completed a pre-NDA (New Drug Application) meeting with the US Food and Drug Administration (USFDA) in May and plans to file in Q2FY26, targeting a potential launch in FY27. Regulatory filings in the EU and emerging markets are scheduled for the second half of FY26. Wockhardt estimates that around 1.1 million patients in India may benefit from Zaynich, while 371,000 carbapenem-resistant cases in the US and Europe are potential candidates. Overall, there are 4.3 million hospitalised cases involving key gram-negative pathogens in the US and EU. The firm sees a combined addressable patient pool of 2 million across India, the US, Europe, and China. Apart from Zaynich, Wockhardt is also betting on other antibiotics in its portfolio, such as Miqnaf (Nafithromycin), and its biotechnology portfolio, including insulin products. Miqnaf, already launched in India, treats community-acquired bacterial pneumonia (CABP) and upper respiratory tract infections. It has received Qualified Infectious Disease Product (QIDP) status from the USFDA, signifying unmet medical need, and Breakthrough Medicinal Product (BMP) designation in Saudi Arabia. Miqnaf targets a ₹10,800-crore market in India, with over 96 million potential prescriptions. In the biosimilars segment, Wockhardt is focusing on diabetes care and sees significant opportunity arising as Danish major Novo Nordisk phases out human insulin cartridges. This creates a ₹450-crore opportunity in India and a $157-million market across emerging economies. With only three major players in India, including itself, Wockhardt expects to benefit substantially. The company is doubling its diabetes biosimilars capacity over the next three years to meet growing demand, targeting business growth of 20–25 per cent.
&w=3840&q=100)
Business Standard
36 minutes ago
- Business Standard
Tata Memorial Centre ties up with Wipro GE to set up cancer research centre
Tata Memorial Centre has tied up with Wipro GE HealthCare Technologies Inc to establish a Cancer Research & Innovation Centre. The collaboration aims to strengthen clinical research and academic engagement activities with the establishment of a 'Joint Working Group' to determine key project areas and a collaboration roadmap for the next five years, Tata Memorial Centre (TMC) said in a statement. "The government is adopting a strategic, policy-driven approach to fight cancer with the establishment of daycare centres, expansion of cancer care ecosystem, promoting cancer screenings and awareness programmes. However, early detection, equitable access and preventive care remain a challenge," Tata Memorial Hospital Director CS Pramesh stated. With Wipro GE HealthCare, TMC aims to enhance clinical research and promote academic engagement to transform personalised cancer care for improved outcomes cancer care, he added. "With this partnership, we strengthen our commitment to connect every step of cancer care right from discovery, diagnosis to treatment, integrating advanced imaging technologies and AI-led solutions in the care continuum," Wipro GE HealthCare South Asia President and CEO Chaitanya Sarawate said. In India, the estimated number of incidences of cancer cases was more than 14 lakhs in 2023, he added. As per industry estimates, around 100 out of every 1 lakh people in India are diagnosed with cancer, and a report from the Cancer Registry Program states the incidence of cancer cases is estimated to increase by 12.8 per cent in 2025 as compared to 2020. Mumbai-based Tata Memorial Centre is a comprehensive cancer care centre under the administrative control of the Department of Atomic Energy, Government of India. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
The Hindu
43 minutes ago
- The Hindu
Stampede deaths: Individual preparedness crucial for safety in public spaces, say doctors
The stampede at the M Chinnaswamy Stadium here, on June 4, during which 11 people died and 47 were injured, draws painful echoes of large-scale crowd disasters which took place during events such as the Maha Kumbh Mela. While the incidents highlight the perilous combination of fan fervour and poor planning, safety in public spaces also requires individual preparedness, say doctors. According to data from the National Crime Records Bureau (NCRB), which was last published in 2022, India arguably has a record of the highest number of stampedes and resultant injuries and fatalities. Between 1996 and 2022, India recorded 3,935 stampedes, resulting in more than 3,000 recorded deaths. During a stampede, people often die not due to trampling, but from a condition called compressive asphyxia, where pressure on the chest prevents normal breathing. A crowd density exceeding six to seven people per square metre can significantly impede movement and breathing, potentially leading to severe oxygen deprivation and death, say doctors. Who's at risk? Sunil Kumar K., lead consultant, interventional pulmonology at Aster CMI Hospital, said that crowded public gatherings can turn hazardous, especially for those with underlying respiratory conditions such as asthma or Chronic Obstructive Pulmonary Disease (COPD). 'Even before a full-blown stampede occurs, the dense human congestion can drastically reduce oxygen availability and increase carbon dioxide inhalation, triggering acute respiratory distress. Individuals in such a situation can experience a surge in panic, heat, and low ventilation, precipitating into a life-threatening illness within minutes,' Dr. Kumar said. Pointing out that people with compromised lungs are especially at risk in these scenarios because they already operate with limited respiratory reserve, the doctor said early symptoms might present as breathlessness, chest tightness, wheezing, or dizziness, which are often mistaken as anxiety. Stressing that safety in public spaces requires individual preparedness as well, he said it is advisable that people with asthma or COPD always carry their rescue inhaler or prescribed medication when attending public events. 'It is also advisable to stay close to exits, to allow for a quick escape if needed,' he said. Compressive asphyxia Ravindra Mehta, senior consultant and head of pulmonology, interventional pulmonology, and sleep medicine at Apollo Hospitals, stated that during a stampede, many people may fall and get trampled. Still, the most common cause of death is compressive asphyxia. This is a dangerous condition that occurs when breathing is prevented in an individual by external pressure on the body, and this is what happened during the stampede on June 4. 'Low oxygen, chest trauma, rib trauma, air leaking around the lungs, bleeding in that area, abdominal bleeding coupled with pain are known to cause major problems. All of these can lead to lung and heart issues. That is why death and demise are known to happen in a stampede,' he said. 'Moreover, there can be a vasovagal reaction—when you are in intense fear and pain, there can be a cardiac arrest secondary to that,' he said. 'Stay upright and try to minimise chest compression by bracing a surface or wall. Whenever a person senses danger, he/she should try to move away from the crowd or try to reach an open space'Ravindra MehtaPulmonologist 'Do not panic' Sachin Kumar, director, pulmonology and critical care medicine at Sakra World Hospital, said it is advisable not to scream in panic as it can increase the fear within the individual and lead to confusion. 'Stay upright and try to minimise chest compression by bracing a surface or wall. Whenever a person senses danger, he/she should try to move away from the crowd, or try to reach an open space,' he said. 'Pushing against an individual leads to hindrance in the expansion of the lungs, resulting in a drop in oxygen and a buildup of carbon dioxide in the blood. Due to the body's response towards lack of oxygen and compression of the chest, one becomes unconscious,' he added.
